Identifying CCR5 coreceptor populations permissive for HIV-1 entry and productive infection: implications for in vivo studies

被引:12
作者
Weichseldorfer, Matthew [1 ]
Tagaya, Yutaka [1 ,2 ]
Reitz, Marvin [1 ,2 ]
DeVico, Anthony L. [1 ,2 ]
Latinovic, Olga S. [1 ,3 ]
机构
[1] Univ Maryland, Sch Med, Inst Human Virol, 725 W Lombard St, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA
[3] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA
关键词
HIV; AIDS pathogenesis; CCR5 coreceptor populations; Conformational changes; PRIMARY-CELLS IMPLICATIONS; CHEMOKINE RECEPTOR CCR5; PROTEIN FLSC IGG1; R5; HIV-1; SYNERGISTIC INHIBITION; MARAVIROC; INDIVIDUALS; MECHANISMS; RESISTANT; SURFACE;
D O I
10.1186/s12967-022-03243-8
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background The chemokine receptor CCR5 is the major coreceptor for HIV-1 cell entry. We previously observed that not all CCR5 mAbs reduce HIV-1 infection, suggesting that only some CCR5 populations are permissive for HIV-1 entry. This study aims to better understand the relevant conformational states of the cellular coreceptor, CCR5, involved in HIV entry. We hypothesized that CCR5 assumes multiple configurations during normal cycling on the plasma membrane, but only particular forms facilitate HIV-1 infection. Methods To this end, we quantified different CCR5 populations using six CCR5 monoclonal antibodies (mAbs) with different epitope specificities and visualized them with super-resolution microscopy. We quantified each surface CCR5 population before and after HIV-1 infection. Results Based on CCR5 conformational changes, down-modulation, and trafficking rates (internalization and recycling kinetics), we were able to distinguish among heterogeneous CCR5 populations and thus which populations might best be targeted to inhibit HIV-1 entry. We assume that a decreased surface presence of a particular CCR5 subpopulation following infection means that it has been internalized due to HIV-1 entry, and that it therefore represents a highly relevant target for future antiviral therapy strategies. Strikingly, this was most true for antibody CTC8, which targets the N-terminal region of CCR5 and blocks viral entry more efficiently than it blocks chemokine binding. Conclusions Defining the virus-host interactions responsible for HIV-1 transmission, including specific coreceptor populations capable of establishing de novo infections, is essential for the development of an HIV-1 vaccine. This study hopefully will facilitate further development of inhibitors to block CCR5 usage by HIV-1, as well as inform future HIV-1 vaccine design.
引用
收藏
页数:12
相关论文
共 55 条
[1]   Homozygous Delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient [J].
Balotta, C ;
Bagnarelli, P ;
Violin, M ;
Ridolfo, AL ;
Zhou, D ;
Berlusconi, A ;
Corvasce, S ;
Corbellino, M ;
Clementi, M ;
Clerici, M ;
Moroni, M ;
Galli, M .
AIDS, 1997, 11 (10) :F67-F71
[2]   Mechanisms regulating chemokine receptor activity [J].
Bennett, Laura D. ;
Fox, James M. ;
Signoret, Nathalie .
IMMUNOLOGY, 2011, 134 (03) :246-256
[3]   Use of G-Protein-Coupled and -Uncoupled CCR5 Receptors by CCR5 Inhibitor-Resistant and -Sensitive Human Immunodeficiency Virus Type 1 Variants [J].
Berro, Reem ;
Yasmeen, Anila ;
Abrol, Ravinder ;
Trzaskowski, Bartosz ;
Abi-Habib, Sarya ;
Grunbeck, Amy ;
Lascano, Danny ;
Goddard, William A., III ;
Klasse, Per Johan ;
Sakmar, Thomas P. ;
Moore, John P. .
JOURNAL OF VIROLOGY, 2013, 87 (12) :6569-6581
[4]   Multiple CCR5 Conformations on the Cell Surface Are Used Differentially by Human Immunodeficiency Viruses Resistant or Sensitive to CCR5 Inhibitors [J].
Berro, Reem ;
Klasse, Per Johan ;
Lascano, Danny ;
Flegler, Ayanna ;
Nagashima, Kirsten A. ;
Sanders, Rogier W. ;
Sakmar, Thomas P. ;
Hope, Thomas J. ;
Moore, John P. .
JOURNAL OF VIROLOGY, 2011, 85 (16) :8227-8240
[5]   Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies [J].
Blanpain, C ;
Vanderwinden, JM ;
Cihak, J ;
Wittamer, V ;
Le Poul, E ;
Issafras, H ;
Stangassinger, M ;
Vassart, G ;
Marullo, S ;
Schlöndorff, D ;
Parmentier, M ;
Mack, M .
MOLECULAR BIOLOGY OF THE CELL, 2002, 13 (02) :723-737
[6]   Targeting CCR5 trafficking to inhibit HIV-1 infection [J].
Boncompain, Gaelle ;
Herit, Floriane ;
Tessier, Sarah ;
Lescure, Aurianne ;
Del Nery, Elaine ;
Gestraud, Pierre ;
Staropoli, Isabelle ;
Fukata, Yuko ;
Fukata, Masaki ;
Brelot, Anne ;
Niedergang, Florence ;
Perez, Franck .
SCIENCE ADVANCES, 2019, 5 (10)
[7]   Association of chemokine-mediated block to HIV entry with coreceptor internalization [J].
Brandt, SM ;
Mariani, R ;
Holland, AU ;
Hope, TJ ;
Landau, NR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (19) :17291-17299
[8]   CCR5 as a Natural and Modulated Target for Inhibition of HIV [J].
Burke, Bryan P. ;
Boyd, Maureen P. ;
Impey, Helen ;
Breton, Louis R. ;
Bartlett, Jeffrey S. ;
Symonds, Geoff P. ;
Huetter, Gero .
VIRUSES-BASEL, 2014, 6 (01) :54-68
[9]   Concordance of CCR5 Genotypes that Influence Cell-Mediated Immunity and HIV-1 Disease Progression Rates [J].
Catano, Gabriel ;
Chykarenko, Zoya A. ;
Mangano, Andrea ;
Anaya, J-M ;
He, Weijing ;
Smith, Alison ;
Bologna, Rosa ;
Sen, Luisa ;
Clark, Robert A. ;
Lloyd, Andrew ;
Shostakovich-Koretskaya, Ludmila ;
Ahuja, Sunil K. .
JOURNAL OF INFECTIOUS DISEASES, 2011, 203 (02) :263-272
[10]   CCR5 inhibitors: Promising yet challenging [J].
Clotet, Bonaventura .
JOURNAL OF INFECTIOUS DISEASES, 2007, 196 (02) :178-180